Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: A tool for noninvasive monitoring of tumor response to therapy

Molecular Imaging and Biology

Volumn 13, Issue 5, 2011, Pages 940-948

  Gainkam, Lea Olive Tchouate ^a   Keyaerts, Marleen ^a,b   Caveliers, Vicky ^a,b   Devoogdt, Nick ^a   Vanhove, Christian ^a,b   Van Grunsven, Leo ^a   Muyldermans, Serge ^a,c   Lahoutte, Tony ^a,b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

99mTc 7C12 nanobody; Bioluminescence imaging; Cetuximab; Epidermal growth factor receptor (EGFR); Erlotinib; Specificity; Therapy monitoring

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 7C12 NANOBODY TC 99M; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOLUMINESCENCE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MONITORING; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SPECIFICITY; DRUG UPTAKE; IN VITRO STUDY; IN VIVO STUDY; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; TUMOR REGRESSION; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; HUMANS; MALE; MICE; MICE, NUDE; NANOSTRUCTURES; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84855689409     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-010-0428-4     Document Type: Article

References (43)

1. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127-137 (Pubitemid 33674041)
2. Rocha-Lima CM, Soares HP, Raez LE, Singal R (2007) EGFR targeting of solid tumors. Cancer Control 14(3):295-304 (Pubitemid 47057800)
3. Marshall J (2006) Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107(6):1207-1218 (Pubitemid 44452768)
4. Fan Z, Masui H, Altas I, Mendelsohn J (1993) Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 53:4322-4432
5. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K (2007) Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 98(8):1275-1280 (Pubitemid 46993549)
6. Paez JG, Jänne PA, Lee JC et al (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304 (5676):1497-1500 (Pubitemid 38720929)
7. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall- cell lung cancer to gefitinib. N Engl J Med 350(21):2129-2139 (Pubitemid 38637993)
8. Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101(36):13306-13311 (Pubitemid 39209661)
9. Mancl EE, Kolesar JM, Vermeulen LC (2009) Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors. Am J Health Syst Pharm 66 (23):2105-2112
10. Pao W, Wang TY, Riely GJ et al (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2(1):e17
11. Cai W, Chen K, He L, Cao Q, Koong A, Chen X (2007) Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 34(6):850-858 (Pubitemid 46798960)
12. Eiblmaier M, Meyer LA, Watson MA et al (2008) Correlating EGFR expression with receptor-binding properties and internalization of 64Cu- DOTA-cetuximab in 5 cervical cancer cell lines. J Nucl Med 49 (9):1472-1479
13. Xu N, Cai G, Ye W et al (2009) Molecular imaging application of radioiodinated anti-EGFR human Fab to EGFR-overexpressing tumor xenografts. Anticancer Res 29(10):4005-4011
14. Velikyan I, Sundberg AL, Lindhe O et al (2005) Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med 46(11):1881-1888 (Pubitemid 46196651)
15. Reilly RM, Kiarash R, Sandhu J et al (2000) A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. J Nucl Med 41(5):903-911 (Pubitemid 30266037)
16. Huang L, Gainkam LO, Caveliers V et al (2008) SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol 10(3):167-175
17. Gainkam LO, Huang L, Caveliers V et al (2008) Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med 49 (5):788-795 (Pubitemid 351717545)
18. Lauwereys M, Arbabi Ghahroudi M et al (1998) Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J 17(13):3512-3520 (Pubitemid 28327370)
19. Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S, Conrath K (2009) General strategy to humanize a camelid singledomain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem 284(5):3273-3284
20. Roovers RC, Laeremans T, Huang L et al (2007) Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR nanobodies. Cancer Immunol Immunother 56(3):303-317 (Pubitemid 46035901)
21. Vanhove C, Defrise M, Bossuyt A, Lahoutte T (2009) Improved quantification in single-pinhole and multiple-pinhole SPECT using micro-CT information. Eur J Nucl Med Mol Imaging 36(7):1049-1063
22. Vanhove C, Defrise M, Lahoutte T, Bossuyt A (2008) Three-pinhole collimator to improve axial spatial resolution and sensitivity in pinhole SPECT. Eur J Nucl Med Mol Imaging 35(2):407-415
23. Loening AM, Gambhir SS (2003) AMIDE: A free software tool for multimodality medical image analysis. Mol Imaging 2(3):131-137
24. Keyaerts M, Verschueren J, Bos TJ et al (2008) Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D-luciferin: Effect on intensity, time kinetics and repeatability of photon emission. Eur J Nucl Med Mol Imaging 35 (5):999-1007
25. O'Connor JP, Jackson A, Asselin MC, Buckley DL, Parker GJ, Jayson GC (2008) Quantitative imaging biomarkers in the clinical development of targeted therapeutics: Current and future perspectives. Lancet Oncol 9:766-776 (Pubitemid 352038315)
26. Sunaga N, Oriuchi N, Kaira K et al (2008) Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer 59(2):203-210 (Pubitemid 351173409)
27. de Geus-Oei LF, Vriens D, van Laarhoven HW, van der Graaf WT, Oyen WJ (2009) Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: A systematic review. J Nucl Med 50 (Suppl 1):43S-54S
28. Kubota K, Ito K, Morooka M et al (2009) Whole-body FDG-PET/CT on rheumatoid arthritis of large joints. Ann Nucl Med 23(9):783-791, Epub 2009 Oct 16
29. Nordberg E, Orlova A, Friedman M et al (2008) In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells. Oncol Rep 19(4):853-7.30
30. Tolmachev V, Friedman M, Sandström M et al (2009) Affibody molecules for epidermal growth factor receptor targeting in vivo: Aspects of dimerization and labeling chemistry. J Nucl Med 50(2):274-283
31. Pal A, Glekas A, Doubrovin M et al (2006) Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 8(5):262-277 (Pubitemid 44446020)
32. Abourbeh G, Dissoki S, Jacobson O et al (2007) Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl Med Biol 34(1):55-70 (Pubitemid 46038157)
33. De Groeve K, Deschacht N, De Koninck C et al (2010) Nanobodies as tools for in vivo imaging of specific immune cell types. J Nucl Med 51 (5):782-789
34. Vaneycken I, Govaert J, Vincke C et al (2010) In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT. J Nucl Med 51(7):1099-1106
35. van Eerd JE, Vegt E, Wetzels JF et al (2006) Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. J Nucl Med 47(3):528-533 (Pubitemid 46768496)
36. Vegt E, Wetzels JF, Russel FG et al (2006) Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med 47(3):432-436 (Pubitemid 46768485)
37. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7(4):301-311 (Pubitemid 40544648)
38. Nogawa M, Yuasa T, Kimura S et al (2005) Monitoring luciferaselabeled cancer cell growth and metastasis in different in vivo models. Cancer Lett 217(2):243-253 (Pubitemid 40023124)
39. Craft N, Bruhn KW, Nguyen BD et al (2005) Bioluminescent imaging of melanoma in live mice. J Invest Dermatol 125(1):159-165 (Pubitemid 40981437)
40. Ling YH, Lin R, Perez-Soler R (2008) Erlotinib induces mitochondrialmediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptor L858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. Mol Pharmacol 74(3):793-806
41. Qian X, Li J, Ding J, Wang Z, Zhang W, Hu G (2009) Erlotinib activates mitochondrial death pathways related to the production of reactive oxygen species in the human non-small cell lung cancer cell line A549. Clin Exp Pharmacol Physiol 36(5-6):487-494
42. Li T, Ling YH, Perez-Soler R (2008) Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene. J Thorac Oncol 3(6):643-647 (Pubitemid 351787310)
43. Atkinson DM, Clarke MJ, Mladek AC, Carlson BL, Trump DP, Jacobson MS, Kemp BJ, Lowe VJ, Sarkaria JN (2008) Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts. Head Neck 30(6):790-799 (Pubitemid 351913857)